CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 1, 2024—Bruker Corp. has entered into a definitive share purchase agreement to acquire EliTechGroup for €870 million (about $940 million) in cash, excluding EliTech’s clinical chemistry business. Bruker expects to close the transaction in the second quarter of this year.
EliTechGroup is headquartered in Turin, Italy, and employs more than 500 people. Its molecular diagnostic business accounts for the majority of the revenues to be acquired. EliTech offers two sample-to-answer molecular diagnostic systems, InGenius and BeGenius, a portfolio of assays for pathogens and viral disease, as well as niche biomedical systems and microbiology products. Its major R&D and operations sites are in Italy, the United States, France, and Germany.
Pages: 1 2